Portage Biotech Inc (PRTG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Portage Biotech Inc (PRTG) has a cash flow conversion efficiency ratio of -2.245x as of September 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.56 Million) by net assets ($695.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Portage Biotech Inc balance sheet independence to measure how much of total assets are equity-financed.
Portage Biotech Inc - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Portage Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Portage Biotech Inc cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Portage Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Portage Biotech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wave Entertainment Public Company Limited
BK:WAVE
|
0.013x |
|
Clal Biotechnology Industries Ltd
TA:CBI
|
-0.033x |
|
Zantat Holdings Berhad
KLSE:0301
|
0.023x |
|
Automobile &Pc
KO:015260
|
0.067x |
|
Decade Resources Ltd
V:DEC
|
-0.028x |
|
Melbana Energy Ltd
AU:MAY
|
-0.017x |
|
5G Networks Ltd
AU:5GN
|
-0.146x |
|
Spolytech Co. Ltd
KQ:050760
|
0.084x |
Annual Cash Flow Conversion Efficiency for Portage Biotech Inc (1998–2025)
The table below shows the annual cash flow conversion efficiency of Portage Biotech Inc from 1998 to 2025. For the full company profile with market capitalisation and key ratios, see PRTG stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $-827.00K | $-5.46 Million | 6.605x | +253.79% |
| 2024-03-31 | $3.33 Million | $-14.30 Million | -4.295x | -2582.00% |
| 2023-03-31 | $75.39 Million | $-12.07 Million | -0.160x | -291.65% |
| 2022-03-31 | $165.43 Million | $-6.76 Million | -0.041x | -40.87% |
| 2021-03-31 | $147.60 Million | $-4.28 Million | -0.029x | -13.81% |
| 2020-03-31 | $145.64 Million | $-3.71 Million | -0.026x | -341.53% |
| 2019-03-31 | $148.56 Million | $-858.00K | -0.006x | +94.82% |
| 2018-03-31 | $9.62 Million | $-1.07 Million | -0.112x | -403.20% |
| 2017-03-31 | $59.59 Million | $-1.32 Million | -0.022x | +95.32% |
| 2016-03-31 | $12.33 Million | $-5.84 Million | -0.474x | +25.43% |
| 2015-03-31 | $4.12 Million | $-2.61 Million | -0.635x | -66.43% |
| 2014-03-31 | $5.07 Million | $-1.94 Million | -0.382x | +36.44% |
| 2013-03-31 | $2.98 Million | $-1.79 Million | -0.600x | -117.39% |
| 2012-03-31 | $4.85 Million | $-1.34 Million | -0.276x | +5.92% |
| 2011-03-31 | $8.94 Million | $-2.62 Million | -0.294x | -457.97% |
| 2010-03-31 | $6.77 Million | $-356.14K | -0.053x | +79.11% |
| 2009-03-31 | $1.14 Million | $-287.38K | -0.252x | -170.28% |
| 2008-03-31 | $5.03 Million | $-468.92K | -0.093x | -16.61% |
| 2007-03-31 | $5.74 Million | $-458.84K | -0.080x | +43.87% |
| 2006-03-31 | $4.53 Million | $-645.50K | -0.142x | +25.05% |
| 2004-03-31 | $1.69 Million | $-321.51K | -0.190x | -127.71% |
| 2003-03-31 | $-214.26K | $-146.90K | 0.686x | +101.34% |
| 2002-03-31 | $3.06K | $-156.80K | -51.310x | -7026.10% |
| 2001-03-31 | $481.93K | $-347.00K | -0.720x | -146.59% |
| 2000-03-31 | $1.60 Million | $-466.90K | -0.292x | +90.95% |
| 1999-03-31 | $106.97K | $-345.09K | -3.226x | -445.75% |
| 1998-03-31 | $-453.32K | $-422.97K | 0.933x | -- |
About Portage Biotech Inc
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors; PORT-6, a highly selective A2A receptor antagonist, which is in phase 1a for the treatment of solid tumors; PORT-8, a dual inhibitor … Read more